, the Swiss drugmaker, is in talks to buy certain operations from Ireland's
, according to a report from London's
The sale would include biotechnology company Elan's flagship multiple sclerosis treatment Tysabri and its Alzheimer's disease pipeline, the newspaper said.
A "well-placed source" confirmed the talks but added that the "complexity of the deal made a decision some way off," the
Strategic talks reportedly were held in May between
and Elan, but they broke down in the early stages.
Elan markets Tysabri with
. The company also is developing a high-profile experimental drug for Alzheimer's disease in partnership with
Back in January, Elan hired
as an adviser to review alternatives, including a minority investment, an alliance, or a merger or sale of the company.